STOCKS TELEGRAPH

Tag: GOVX Stock

  • GeoVax Labs (GOVX) Gains Pre-Market Momentum With Critical Vaccine Trial Award

    GeoVax Labs (GOVX) Gains Pre-Market Momentum With Critical Vaccine Trial Award

    GeoVax Labs, Inc. (NASDAQ: GOVX) shares have observed a notable rise following the award of a substantial trial contract. During the pre-market session, GOVX shares surged by 8.42%, reaching $2.06, building on a previous session’s impressive increase of 69.64%, which closed at $1.90.

    Finances For The Clinical Trial

    The funding from the Rapid Response Partnership Vehicle, or RRPV, will help develop GeoVax’s (GOVX) next-generation COVID-19 vaccine, GEO-CM04S1. The RRPV is funded by the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS).

    This agreement includes a clinical research with 10,000 participants in Phase 2b. Its goal is to compare the safety, immunogenicity, and efficacy of GEO-CM04S1 to an mRNA COVID-19 vaccination that has received FDA approval. The trial preparations are underway, with BARDA committing approximately $24.3 million initially, potentially increasing to $45 million.

    This funding will cover the manufacturing of clinical materials and regulatory support for the Phase 2b trial. Additional awards from BARDA’s Clinical Studies Network will provide around $343 million to execute the trial using GeoVax’s vaccine, under the Project NextGen program.

    Innovative Vaccine Development

    The funding supports both GeoVax’s MVA platform for infectious illnesses and provides essential resources for the development of GEO-CM04S1. Although first-generation COVID-19 vaccinations were effective during the height of the epidemic, their protective range and longevity are limited, requiring regular updates.

    By promoting long-lasting neutralizing antibody and T-cell-based immunity against both present and future SARS-CoV-2 variants, GEO-CM04S1 seeks to overcome these constraints. The vaccine developed by GeoVax has continuously shown strong immune responses and has the potential to provide long-lasting and comprehensive clinical protection. It is expected that the start of the Phase 2b research will confirm the benefits and effectiveness of GeoVax’s novel technology.

    Funding for this initiative is part of Project NextGen, a $5 billion effort by HHS to develop new vaccines and therapeutics offering broader and more enduring protection against COVID-19 than those provided by the first-generation vaccines.

  • GeoVax Labs (GOVX) Stock Makes Stellar Gains

    GeoVax Labs Inc. (NASDAQ: GOVX) is a biotechnology company that specializes in developing and commercializing treatments for various cancers and viral conditions. Many describe GeoVax as being at the forefront of the global battle against several deadly viruses, including the Zika condition. It has recently been making terrific strides in the market, due to some hot updates.

    GOVX Rallies with Zika Patent Acquisition

    The big news for GeoVax Labs Inc. (GOVX) relates to its recent achievement of finally getting a patent for its Zika virus treatment from the US Patent and Trademark Office. The development is a major milestone for the company, as it protects its IP in the market, and makes the company a formidable name in the global fight against the Zika virus. The particular object of this patent protection is the modified vaccinia Ankara platform, which the company expects to be a breakthrough against the Zika virus, along with future strains. Its safety record stands as being spectacular, based on the studies performed.

    GeoVax to Present at the BioGEO Investor and CEO Conference for 2023

    Another potential catalyst that has GOVX stock in the spotlight of the market may link to its upcoming spot in the biotech world’s much-awaited BioGEO Conference, where CEOs of top firms will be interacting with investors and industry stakeholders. The recent patent approval is highly likely to be discussed within the venue, along with other pipeline-related developments that GeoVax has undertaken in recent years. Most important, however, would be its future roadmap, and its ability to execute these ambitions.

    Conclusion

    GOVX stock has been on a roll, and recent updates have been fueling this upward growth. With solid fundamentals and bright prospects, the stock seems to be gaining quite some exposure among market players. Only time will ultimately tell how far this beast may actually fly.

  • GeoVax Labs Inc. (GOVX)’s Malaria Vaccine Patent Rally Ends Up Under Corrections Premarket

    Yesterday, the vaccines developer biotech, GeoVax Labs Inc. (GOVX) announced a patent for its malaria vaccine candidate. Coming on the heels of a cancer vaccine patent, the news had GOVX stock rally big during intraday trading. The stock was able to amass 29.20% in the session while a heft volume of 3,474% of the average shares exchanged. At the close of yesterday’s trading, the stock was valued at $1.11 per share.

    Source: Technology Networks

    Today, on April 27, the stock has fallen under corrections to shed its gains in the premarket. At the time of writing, GOVX was trading at a price of $1.02 after losing 8.11%.

    GOVX’s Malaria Vaccine Patent

    The company had recently filed a patent application with the U.S Patent and Trademark Office for its malaria vaccine candidate. On Tuesday, the company said that the patent application was successful and it has been issued Patent No. 11,311,612 for the vaccine.

    While most of the existing vaccine candidates for malaria are based on proteins that target only one stage of the parasite’s life cycle, GOVX’s candidate has antigens from multiple stages of the parasite’s life cycle. Thus, the company’s vaccine MVA-VLP has much potential to offer a broader response against the disease.

    The World of Vaccines Post-Pandemic

    Covid-19 has forever changed the world, ushering in a new era of vaccine production. While before the pandemic around 5 billion vaccine doses were produced annually, the figures have dramatically increased to 11 billion doses of Covid vaccines alone in just 2021.

    Another advancement brought about by the pandemic is the new mRNA technology used in Pfizer and Modrena’s Covid vaccines. Before the majority of vaccines were inactivated vaccines or attenuated ones. The mRNA technology is shuffling the industry with now many focused on bringing mRNA-based vaccines for numerous diseases.

    The global vaccine sales market is expected to register a CAGR of 6.15% from 2022 to 2027 with its projected value being $353.04 billion for 2027.

    GOVX’s Performance & Outlook

    The company is currently focused on developing its Covid-19 vaccine which is in Phase 2 clinical trials while its lead cancer product is in Phase ½ clinical trial for head and neck cancer. The cancer vaccine candidate was recently issued a patent in March 2022, following which its malaria vaccine candidate also received a patent yesterday. In addition, the company is also developing vaccines for Ebola and Zika viruses which have so far shown positive potential in preclinical studies.

    GOVX will be reporting its Q1 fiscal 2022 financial results today after the market closes. Analysts are expecting the vaccine maker to report losses of $0.40 per share for the quarter while the previous quarter’s earnings stood at -$2.24 per share.

  • Will GeoVax Labs Inc. (GOVX) bean ideal investment for long-term investors?

    On 10th March 2021, GeoVax Labs Inc. (GOVX) got invited to present at the Maxim Group’s Inaugural Emerging Growth Virtual Conference that is to be held on 17th-18th March 2021. The company will present its recent developments in vaccine research and GeoVax’s immunotherapy. The next day, GeoVax’s stock went up by 15.38% to close at $5.55.

    GeoVax Labs, Inc.

    GeoVax is a biotech company whose primary goal is to develop effective and safe vaccines and immunotherapies against various infectious diseases such as Ebola and Zika Virus, and cancers. The company was established primarily to develop a vaccine for curing HIV-1. Still, eventually, the company moved on to create vaccines for various human severe diseases for which there does not exist a cure.  According to GeoVax, the vaccines they make are developed on a sturdy, safe, suitable for repeated use and affordable for both routine vaccination and in case of an epidemic. GeoVax’s HIV program is now successfully advancing towards multiple human clinical trials, and its other programs are at different stages of pre-clinical testing.

    GeoVax’s fight against the Epidemic

    On 11th January 2021, GeoVax Labs In. announced that a part of the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), has awarded them the grant to develop a vaccine to help fight against the worldwide pandemic, COVID-19. GeoVax is currently working on developing a vaccine that will help provide a prolonged protective immunity against the COVID-19 and avoid the potential side effects of the vaccine. Later on 10th March 2021, GeoVax Labs Inc. (GOVX) got invited to present at the Maxim Group’s Inaugural Emerging Growth Virtual Conference that is to be held on 17th-18th March 2021. During the virtual conference, the chairman and CEO of GeoVax Labs Inc., David Dodd, will overview their progress in vaccine research and immunotherapy, emphasisingGeoVax’s COVID-19 vaccine program and cancer immunotherapy programs. Mark Newman, Ph.D., the company’s ChiefScientific Officer, will also be a part of the panel discussion regarding its programs’ developments. Investors have the option of attending the virtual conference by registering and can also request to arrange a one-to-one meeting with the company’s CEO after the panel concludes.

    All things considered

    In the light of the given information, investors reacted positively to the news of GeoVax presenting at the virtual conference and the fact that they will be allowed to attend the meeting and have a one-to-one discussion with Mr. Dodd after the session has concluded.

  • GeoVax Labs (NASDAQ: GOVX) Stock Is Soaring. Here’s Why

    GeoVax Labs (NASDAQ: GOVX) Stock Is Soaring. Here’s Why

    Shares of GeoVax Labs, Inc. (NASDAQ: GOVX) kicked off Monday’s session with an increase of 23.36% in its share prices. The strong performance of the company highlighted the positive sentiments of the investor after the company announced that it has signed a license agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to support the COVID-19 vaccine development.

    The Patent and Biological Materials License Agreement will give access to NIAID’s patent rights in the stabilized SPIKE protein to GeoVax.  SPIKE protein is the protein that is used by SARS-CoV-2 to enter the human tissue. This new agreement with NIAID will give GeoVax rights to manufacture, develop, and commercialize its COVID-19 vaccine.

    GeoVax Labs, Inc. (NASDAQ: GOVX) shares were trading up 23.36% at $3.75 at the time of writing on Monday. GeoVax Labs, Inc. (GOVX) share price went from a low point around $2.30 to briefly over $92.00 in the past 52 weeks. It has traded up 62.76% from its 52-weeks low and moved down -95.92% from its 52-weeks low. GOVX market cap has remained high, hitting $10.79 million at the time of writing. It had a trading volume of 14.67 million as compared to the average volume of 134.56K.

    After signing an agreement with NIAID, GeoVax will be able to use the materials and patent rights owned by agencies of the US Department of Health and Human Services (HHS). This is an important agreement for GeoVax in the current development of its COVID-19 vaccine. The company has designed and constructed four COVID-19 vaccine candidates.

    Additionally, GeoWax continues to actively discuss additional funding support. The company is striving to secure the necessary manufacturing resources to advance medical development as soon as possible.